Eamonn Quigley (MD & Professor), Chairman of the Advisory Board
Professor Eamonn Quigley is Chief of Gastroenterology at The Methodist Hospital in Houston, Texas and a Principal Investigator at the Alimentary Pharmabiotic Centre (APC) at University College Cork (UCC), in Cork, Ireland. A graduate of UCC, Professor Quigley trained in internal medicine in Glasgow and Manchester and in gastroenterology in Glasgow, the Mayo Clinic, Rochester, Minnesota and Manchester. In 1986 he joined the faculty at the University of Nebraska Medical Center in Omaha, Nebraska where he ultimately served as Chief of Gastroenterology and Hepatology. Returning to Cork in 1998 he served as Dean of the Medical School at UCC for 7 years and has been a principal investigator at the APC since its inception. He took up his current position in January 2013. He served as president of both the American College of Gastroenterology and the World Gastroenterology Organisation and is a past editor-in-chief of the American Journal of Gastroenterology
Fergus Shanahan (MD)
Fergus is Professor and Chair of the Department of Medicine at University College Cork (UCC). He is a UCD medical graduate and was awarded the gold medal in medicine from the Mater Hospital, Dublin. After internship and residency in internal medicine in Dublin, he trained in Clinical Immunology at McMaster University, Canada and in Gastroenterology at the University of California, Los Angeles (UCLA). He has been awarded Fellowships from the Royal College of Physicians in Ireland, Canada and the United Kingdom and the Fellowship of the American College of Physicians. Before returning to Ireland in 1993 he was Associate Professor of Medicine with tenure at UCLA. He has published over 300 peer reviewed scientific articles and several books.
Declan Doogan (MD)
Declan is currently President of Research and Development for Amarin Corporation Plc. Through his 25 years in the Pharmaceutical Industry, Declan has a wealth of experience in the management of drug development. During his career with Pfizer he headed the research and development group in Japan and the UK and in 2003 was appointed the worldwide head for Pfizer Research and Development based in the U.S. Dr. Doogan received his medical degree from Glasgow University and is a Fellow of the Royal College of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the UK.
Ted Dinan (MD)
Ted is Professor of Psychiatry and a Principal Investigator in the Alimentary Pharmabiotic Centre at University College Cork. He was previously Chair of Clinical Neurosciences and Professor of Psychological Medicine at St. Bartholomew's Hospital, London. Prior to that he was a Senior Lecturer in Psychiatry at Trinity College Dublin. He has worked in research laboratories on both sides of the Atlantic and has a PhD in Pharmacology from the University of London. He is a Fellow of the Royal Colleges of Physicians and Psychiatrists and a Fellow of the American College of Physicians. He has published over 200 papers and numerous books on the pharmacology and neurobiology of affective disorders. His primary research focus is on immune and endocrine aspects of depression and irritable bowel syndrome.
Liam received his BSc in Microbiology from University College Cork in 1994 and his PhD in Immunology was awarded in 1998 by Trinity College Dublin. Thereafter, he performed post-doctoral research at the Department of Microbiology and the Department of Medicine, University College Cork and the Digestive Diseases Division, UCLA. He was a Principal Investigator at the Alimentary Pharmabiotic Centre, University College Cork, from 2003 to 2008. Since 2009, he is the head of Molecular Immunology at the Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland. His research interests are focused on the molecular basis for microbe and metabolite modulation of mucosal inflammatory responses. He is a co-author on 61 published articles and is a co-inventor on 7 granted patents. Liam is a co-founder of Alimentary Health Pharma Davos, which specialises in commercialising microbial technologies as pharmaceutical products.